Sugi Predict

Sugi Predict / Compounds / SCHEMBL659202

SCHEMBL659202

SCHEMBL659202

O=C1C(=Cc2ccccc2)C(c2ccccc2)C1=Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 5/20 0.55
▸ CYP1A2 P05177 4/20 0.51
▸ MAPT P10636 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ NFKB1 P19838 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ TP53 P04637 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ F3 P13726 1/20 0.42
▸ PTPN1 P18031 1/20 0.41
▸ F2 P00734 3/20 0.40
▸ F10 P00742 3/20 0.40
▸ MIF P14174 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342723 0.98 CYP19A1 (0.54) CYP19A1CYP1A2MAPTLMNANPSR1
SCHEMBL1343233 0.98 CYP19A1 (0.54) CYP19A1CYP1A2MAPTLMNANPSR1
SCHEMBL1720443 0.82 CYP19A1 (0.81) CYP19A1CYP1A2MAPTLMNANPSR1
SCHEMBL18130143 0.71 ALDH1A1 (0.42) CYP19A1CYP1A2MAPTLMNACYP2C19
SCHEMBL18130144 0.71 ALDH1A1 (0.42) CYP19A1CYP1A2MAPTLMNACYP2C19
SCHEMBL9145030 0.71 NFKB1 (0.42) CYP19A1CYP1A2MAPTLMNANPSR1
SCHEMBL9165216 0.68 CYP19A1 (0.56) CYP19A1CYP1A2MAPTLMNANPSR1
SCHEMBL29856911 0.68 MAPT (1.00) CYP1A2MAPTLMNANPSR1CYP2D6
SCHEMBL22462351 0.68 F10 (0.68) CYP1A2MAPTLMNAMAPK1F3
SCHEMBL22462352 0.68 F10 (0.68) CYP1A2MAPTLMNAMAPK1F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117886393-B Method for degrading cultivation wastewater by catalytic oxidation 广东华绿环保科技有限公司 2024-07-09 — — CN claimed
CN-117886393-A Method for degrading cultivation wastewater by catalytic oxidation 广东华绿环保科技有限公司 2024-04-16 — — CN claimed
CN-114478599-B Boron-containing organic fluorescent molecule and preparation method and application thereof 南京工业大学 2023-10-13 — — CN claimed
CN-116199681-A Hole transport material with anchoring and passivation effects, preparation method thereof, perovskite solar cell and preparation method thereof 广东工业大学 2023-06-02 — — CN claimed
CN-117886393-B Method for degrading cultivation wastewater by catalytic oxidation 广东华绿环保科技有限公司 2024-07-09 — — CN disclosed
WO-2024131938-A1 QUINAZOLINE COMPOUND AND USE THEREOF 赛诺哈勃药业（成都）有限公司 2024-06-27 — — WO disclosed
CN-118164966-A MAT2A inhibitor and application thereof 恒元生物医药科技(苏州)有限公司 2024-06-11 — — CN disclosed
CN-114891032-B Monoboro derivative based on fluorene-based aniline fusion donor, preparation and application thereof 华中科技大学 2024-05-14 — — CN disclosed
CN-118043325-A 8-Oxo-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-05-14 — — CN disclosed
CN-117946138-A And ring nitrogen-containing compound, intermediate thereof, preparation method and application 杭州圣域生物医药科技有限公司 2024-04-30 — — CN disclosed
CN-117940417-A Halogen substituted pyridazinone compounds and application thereof 南京明德新药研发有限公司 2024-04-26 — — CN disclosed
CN-117886393-A Method for degrading cultivation wastewater by catalytic oxidation 广东华绿环保科技有限公司 2024-04-16 — — CN disclosed
US-20080191614-A1 Novel Deuterated Aryl Amine Compound, Preparation Method Thereof, and Organic Light Emitting Diode Using The Same DOOSAN CORPORATION (KR) 2008-08-14 — — US disclosed
WO-2008091130-A1 ASYMMETRIC STYRYL DERIVATIVES AND ORGANIC LIGHT EMITTING DIODE PREPARED USING THE SAME DOOSAN CORPORATION (KR) 2008-07-31 — — WO disclosed
WO-2006121237-A1 NOVEL DEUTERATED ARYL AMINE COMPOUND, PREPARATION METHOD THEREOF, AND ORGANIC LIGHT EMITTING DIODE USING THE SAME DOOSAN CORPORATION (KR) 2006-11-16 — — WO disclosed
EP-0962457-B1 Piperidones as tachykinin antagonists PFIZER LTD (GB) 2003-08-06 — — EP disclosed
EP-1204675-B1 STREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME AVENTIS PHARMA SA (FR) 2003-05-21 — — EP disclosed
EP-1204675-A1 STREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME Aventis Pharma S.A. (FR) 2002-05-15 — — EP disclosed
WO-2001010895-A1 STREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME AVENTIS PHARMA S.A. (FR) 2001-02-15 — — WO disclosed
EP-0962457-A1 Piperidones as tachykinin antagonists Pfizer Limited (GB) 1999-12-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080191614-A1 Novel Deuterated Aryl Amine Compound, Preparation Method Thereof, and Organic Light Emitting Diode Using The Same ARNT, TYR, AHR CYP19A1 177/4885CYP1A2 176/4885MAPT 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.